New insider activity at Celcuity ( (CELC) ) has taken place on November 21, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director Richard E Buller has made a significant move by selling 3,900 shares of Celcuity stock, amounting to a total transaction value of $377,247.
Recent Updates on CELC stock
In the past 24 hours, Celcuity Inc. announced the submission of its New Drug Application (NDA) to the FDA for gedatolisib, targeting a specific type of advanced breast cancer, marking a significant milestone for the company. This announcement, coupled with promising Phase 3 trial results, has influenced recent analyst ratings and price targets. Wolfe Research initiated coverage with an Outperform rating, citing the potential for further positive trial results and acquisition interest from big pharma. Conversely, H.C. Wainwright downgraded Celcuity to Neutral, noting the stock’s substantial year-to-date appreciation and suggesting that current prices reflect perfection, implying more downside risk. Despite these mixed analyst views, Celcuity’s recent earnings call highlighted strong clinical progress and financial positioning, although increased financial losses and regulatory uncertainties remain challenges. The company’s market potential is robust, with significant projected revenues, but pending FDA approval and additional data requirements pose risks.
Spark’s Take on CELC Stock
According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.
Celcuity’s stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company’s financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.
To see Spark’s full report on CELC stock, click here.
More about Celcuity
YTD Price Performance: 615.92%
Average Trading Volume: 1,104,033
Technical Sentiment Signal: Buy
Current Market Cap: $4.36B